keyword
MENU ▼
Read by QxMD icon Read
search

Infliximab

keyword
https://www.readbyqxmd.com/read/29352847/switching-to-biosimilar-infliximab-real-world-data-in-patients-with-severe-inflammatory-arthritis
#1
Christopher R Holroyd, Lucy M Parker, Sarah Bennett, Jalaa Zarroug, Caron Underhill, Brian Davidson, Ray Armstrong, Nicholas C Harvey, Elaine Dennison, Cyrus Cooper, Christopher J Edwards
No abstract text is available yet for this article.
January 15, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29352387/current-perspectives-on-erythema-multiforme
#2
REVIEW
Marianne Lerch, Carlo Mainetti, Benedetta Terziroli Beretta-Piccoli, Thomas Harr
Recognition and timely adequate treatment of erythema multiforme remain a major challenge. In this review, current diagnostic guidelines, potential pitfalls, and modern/novel treatment options are summarized with the aim to help clinicians with diagnostic and therapeutic decision-making. The diagnosis of erythema multiforme, that has an acute, self-limiting course, is based on its typical clinical picture of targetoid erythematous lesions with predominant acral localization as well as histological findings...
January 19, 2018: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29349693/anti-tumor-necrosis-factor-%C3%AE-induced-dermatological-complications-in-a-large-cohort-of-inflammatory-bowel-disease-patients
#3
P Andrade, S Lopes, R Gaspar, A Nunes, S Magina, G Macedo
BACKGROUND/AIMS: The broader use of anti-tumor necrosis factor (TNF) agents in inflammatory bowel disease (IBD) has been associated with a high rate of adverse reactions. Dermatological complications are among the most common adverse events. We assessed the incidence, risk factors, management, and outcome of anti-TNF-induced dermatological complications in a large cohort of IBD patients. METHODS: This was an observational retrospective study at a single tertiary referral center...
January 18, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29342997/-x-linked-inhibitor-of-apoptosis-deficiency-manifested-as-crohn-s-disease-a-case-report-and-literature-review
#4
L J Xu, Y Y Luo, J D Yu, J G Lou, Y H Fang, J Chen
Objective: To analyze the clinical characteristics of X-linked inhibitor of apoptosis (XIAP) deficient patients with clinical manifestation of Crohn's disease. Methods: Clinical manifestations, laboratory investigations, genetic testing and therapeutic interventions of one case of XIAP deficiency who was admitted to Department of Gastroenterology in Children's Hospital, Zhejiang University School of Medicine in May 2016 were summarized. PubMed and Chinese database for articles published from January 2016 to June 2017 were searched using the key words of'Crohn's disease'and'XIAP', and the relevant literature was reviewed...
January 2, 2018: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/29340807/long-term-outcome-of-infliximab-optimization-for-overcoming-immunogenicity-in-patients-with-inflammatory-bowel-disease
#5
Konstantinos Papamichael, Ravy K Vajravelu, Mark T Osterman, Adam S Cheifetz
BACKGROUND: Preliminary data suggest that treatment optimization can reverse immunogenicity and regain response in patients with IBD and secondary loss of response (SLR) to anti-TNF therapy due to antidrug antibodies. However, data regarding the long-term outcome of these patients are scarce. AIMS: We aimed to investigate drug retention in IBD patients of whom infliximab was optimized to overcome immunogenicity and variables associated with drug retention. METHODS: This was a retrospective, multicenter study of consecutive IBD patients with antibodies to infliximab (ATI), based on either proactive or reactive therapeutic drug monitoring, who underwent infliximab optimization (increasing dose, shortening interval, adding an immunomodulator, or combination) to overcome immunogenicity from September 2012 to July 2015; they were followed through December 2015...
January 16, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29335342/comparative-efficacy-of-tumor-necrosis-factor-%C3%AE-inhibitors-in-ankylosing-spondylitis-a-systematic-review-and-bayesian-network-metaanalysis
#6
Runsheng Wang, Abhijit Dasgupta, Michael M Ward
OBJECTIVE: To compare the efficacy of 6 tumor necrosis factor-α inhibitors (TNFi) in treatment of ankylosing spondylitis (AS) at 12 weeks and 24 weeks. METHODS: We performed a systematic literature review of randomized controlled trials of TNFi in patients with active AS. We included trials that reported efficacy at 10 to 14 weeks (12-week analysis) and at 24 to 30 weeks (24-week analysis). We used Bayesian network metaanalysis (NMA) to compare their relative efficacy to improve the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and C-reactive protein (CRP) level...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29333082/a-fcgr3a-polymorphism-predicts-anti-drug-antibodies-in-chronic-inflammatory-bowel-disease-patients-treated-with-anti-tnf
#7
Patricia Romero-Cara, Daniel Torres-Moreno, José Pedregosa, Juan Antonio Vílchez, María Sergia García-Simón, Guadalupe Ruiz-Merino, Senador Morán-Sanchez, Pablo Conesa-Zamora
BACKGROUND: The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC). Since receptors for the Fc portion of IgG (FCGRs) are involved in the degradation of IgG complexes, we hypothesised that a polymorphism in FCGR3A (V158F; rs396991) gene could be involved in anti-TNF ADA generation and treatment resistance...
2018: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29332708/management-of-psoriasis-in-patients-with-inflammatory-bowel-disease-from-the-medical-board-of-the-national-psoriasis-foundation
#8
REVIEW
Scott M Whitlock, Clinton W Enos, April W Armstrong, Alice Gottlieb, Richard G Langley, Mark Lebwohl, Joseph F Merola, Caitriona Ryan, Michael P Siegel, Jeffrey M Weinberg, Jashin J Wu, Abby S Van Voorhees
BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017...
February 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29332199/analysis-of-the-data-on-pregnancy-and-lactation-provided-by-patient-information-leaflets-of-anti-rheumatic-drugs-in-argentina
#9
Miguel Ormaza Sabando, Maira Arias Saavedra, Gabriel Sequeira, Eduardo Kerzberg
To analyse the level of consistency and updating of the information on pregnancy and lactation provided by patient information leaflets (PILs) of the antirheumatic drugs approved in Argentina. Inconsistencies between the 2016 EULAR Task Force recommendations on the use of anti-rheumatic drugs during pregnancy and lactation and the information provided by PILs of the same drugs approved in Argentina were analysed along with inconsistencies within the PILs of different registered trademarks of these drugs. Eighty-eight PILs of 32 drugs were analysed...
January 13, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29330783/clinical-pharmacokinetics-and-pharmacodynamics-of-infliximab-in-the-treatment-of-inflammatory-bowel-disease
#10
REVIEW
Amy Hemperly, Niels Vande Casteele
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). It has been shown to induce and maintain both clinical remission and mucosal healing in pediatric and adult patients with inflammatory bowel disease (IBD) who are unresponsive or refractory to conventional therapies. The administration of infliximab is weight-based and the drug is administered intravenously. The volume of distribution of infliximab is low and at steady state ranges from 4...
January 12, 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29329557/one-year-risk-of-serious-infection-in-patients-treated-with-certolizumab-pegol-as-compared-with-other-tnf-inhibitors-in-a-real-world-setting-data-from-a-national-u-s-rheumatoid-arthritis-registry
#11
Leslie R Harrold, Heather J Litman, Katherine C Saunders, Kimberly J Dandreo, Bernice Gershenson, Jeffrey D Greenberg, Robert Low, Jeffrey Stark, Robert Suruki, Srihari Jaganathan, Joel M Kremer, Mohamed Yassine
BACKGROUND: Registry studies provide a valuable source of comparative safety data for tumor necrosis factor inhibitors (TNFi) used in rheumatoid arthritis (RA), but they are subject to channeling bias. Comparing safety outcomes without accounting for channeling bias can lead to inaccurate comparisons between TNFi prescribed at different stages of the disease. In the present study, we examined the incidence of serious infection and other adverse events during certolizumab pegol (CZP) use vs other TNFi in a U...
January 2, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29323542/the-comparative-efficacy-of-brodalumab-in-patients-with-moderate-to-severe-psoriasis-a-systematic-literature-review-and-network-meta-analysis
#12
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons, Anders Holmen Møller
PURPOSE: To evaluate the relative efficacy of brodalumab compared with approved biologic therapies and apremilast for moderate-to-severe psoriasis. METHODS: We searched MEDLINE, Embase and Cochrane for randomized controlled trials reporting induction phase responses. The primary analysis examined the proportion of patients achieving Psoriasis Area Severity Index (PASI) 50, 75, 90 or 100 responses using a random-effects Bayesian multinomial likelihood model with probit link, with and without adjustment for variation in study-level placebo responses...
January 11, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29317275/increasing-infliximab-dose-based-on-symptoms-biomarkers-and-serum-drug-concentrations-does-not-increase-clinical-endoscopic-or-corticosteroid-free-remission-in-patients-with-active-luminal-crohn-s-disease
#13
Geert D'Haens, Severine Vermeire, Guy Lambrecht, Filip Baert, Peter Bossuyt, Benjamin Pariente, Anthony Buisson, Yoram Bouhnik, Jérôme Filippi, Janneke Vander Woude, Philippe Van Hootegem, Jacques Moreau, Edouard Louis, Denis Franchimont, Martine De Vos, Fazia Mana, Laurent Peyrin-Biroulet, Hedia Brixi, Matthieu Allez, Philip Caenepeel, Alexandre Aubourg, Bas Oldenburg, Marieke Pierik, Ann Gils, Sylvie Chevret, David Laharie
BACKGROUND & AIMS: A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold. We performed a prospective, randomized trial to determine whether therapeutic drug monitoring (TDM) to maintain serum levels of infliximab above 3 μg/mL produced higher rates of clinical and endoscopic remission than adapting dose based only on symptoms...
January 6, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29315163/efficacy-and-safety-of-adalimumab-in-pediatric-ulcerative-colitis-a-real-life-experience-from-the-sigenp-ibd-registry
#14
Marina Aloi, Matteo Bramuzzo, Serena Arrigo, Claudio Romano, Giulia D'Arcangelo, Doriana Lacorte, Simona Gatti, Maria Teresa Illiceto, Francesca Zucconi, Dario Dilillo, Giovanna Zuin, Daniela Knafelz, Alberto Ravelli, Salvatore Cucchiara, Patrizia Alvisi
OBJECTIVES: The aim of this study was to evaluate the effectiveness and safety of adalimumab (ADA) in children with ulcerative colitis (UC) previously treated with infliximab (IFX). METHODS: Retrospective study including children with UC from a national registry who received ADA therapy. The primary endpoint was the rate of corticosteroid (CS) free remission at week 52. Secondary outcomes were: the rate of sustained clinical remission, primary non-response and loss of response at weeks 12, 30, and 52 and rate of mucosal healing (MH) and side effects at week 52...
January 6, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29314738/long-term-efficacy-and-safety-of-add-on-tacrolimus-for-persistent-active-rheumatoid-arthritis-despite-treatment-with-methotrexate-and-tumor-necrosis-factor-inhibitors
#15
Taio Naniwa, Shiho Iwagaitsu, Mikiko Kajiura
AIM: To assess the long-term efficacy and safety of adding tacrolimus for patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor (TNF) therapy with methotrexate. METHODS: Consecutive patients who were treated with adding tacrolimus onto anti-TNF therapy with methotrexate for active RA despite anti-TNF therapy with methotrexate, were retrospectively analyzed in terms of treatment response, achieving remission, subsequent treatment tapering and adverse events...
January 4, 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29314136/editorial-mitigating-primary-nonresponse-to-infliximab-are-we-better-equipped-now
#16
EDITORIAL
D Sawbridge, S Subramanian
No abstract text is available yet for this article.
February 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29310493/drug-concentrations-and-anti-drug-antibodies-during-treatment-with-biosimilar-infliximab-ct-p13-in-routine-care
#17
B Glintborg, T Kringelbach, N Bolstad, D J Warren, G Eng, I J Sørensen, A G Loft, O Hendricks, Imj Hansen, A Linauskas, H Nordin, S Kristensen, H Lindegaard, D V Jensen, G L Goll, E Høgdall, J Gehin, C Enevold, C H Nielsen, N S Krogh, J S Johansen, M L Hetland
No abstract text is available yet for this article.
January 9, 2018: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/29308287/rapid-loss-of-efficacy-of-biosimilar-infliximab-in-three-patients-with-beh%C3%A3-et-s-disease-after-switching-from-infliximab-originator
#18
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi
Three patients affected by Behçet's disease (BD) with severe uveitis and neurological involvement in stable clinical remission and who rapidly relapsed after switching from reference infliximab (re-IFX) to biosimilar infliximab (bio-IFX) are reported. In order to observe the rules of local health authorities, two males and one female (38, 26, and 40 years old, respectively) with BD complicated by severe uveitis and neuro-Behçet and who were in prolonged remission, were switched from re-IFX to bio-IFX, with the same dosing regimen of 5 mg/kg intravenous infusions every 8 weeks...
December 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/29308279/the-real-world-use-of-different-anti-tumor-necrosis-factor-agents-in-a-northern-european-population-of-patients-with-beh%C3%A3-et-s-disease
#19
Fahd Adeeb, Wan Lin Ng, Maria Usman Khan, Joseph Devlin, Austin G Stack, Alexander Duncan Fraser
Objective: The aim of this study was to evaluate prescription practices, treatment responses, and serious adverse events of anti-tumor necrosis factor (anti-TNF) therapies in Behçet's disease (BD). Material and Methods: Patients with BD satisfying the International Study Group for Behçet's Disease or the International Criteria for Behçet's Disease criteria were recruited from a regional rheumatology program. The choice of anti-TNF, treatment response, and adverse events were specified...
December 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/29304271/blau-jabs-syndrome-in-a-tertiary-ophthalmologic-center
#20
Heloisa Nascimento, Jacqueline M Sousa, Délia González Fernández, Gustavo H A Salomão, Elcio H Sato, Cristina Muccioli, Rubens Belfort
In a prospective case series of patients with Blau-Jabs syndrome (BJS) conducted in the Ophthalmology Department/Federal University of Sao Paulo, seven patients with clinical and ophthalmologic manifestations of the disease and a positive genetic test result for the presence of a mutation in the CARD15/NOD2 gene were followed for a minimal period of 1 year. All patients had uveitis, five had nummular corneal subepithelial opacities, and four had multifocal choroiditis. Oral prednisolone was administered to all patients; inflammation was controlled in six patients with at least one immunosuppressive drug...
January 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
1757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"